Some of the first clinical data for a potential coronavirus treatment showed it did not help.
This was in regards to patients with severe cases of COVID-19, according to Business Insider.
Scientists in China enrolled 199 coronavirus patients into a study from January 18 through February 3.
They randomly assigned them to get either the HIV drug Kaletra plus standard of care or just regular care.
The drug did not show benefits in keeping patients alive, unfortunately.
It also did not reduce the amount of virus in patients or shorten their hospital stays.